Alicaforsen
Phase
Phase3Study status
CompletedView details
IONIS PHARMACEUTICALS INC
IndicationCrohn's Disease
Actual study completion2002-04-27
Cash and cash equivalents · Restricted cash and marketable securities excluded
Cash verified Nov 16, 2026
Next verified event · Clinical readout window
IgAN
Phase 3
Announced Nov 9, 2026 · Announced window
Official announcementProgram: Sefaxersen; IMAgINATION data | | •; announced 2027 data window.
Clinical readout window
Angelman syndrome
Phase 3
Announced Nov 9, 2026 · Announced window
Official announcementCompleted enrollment in the Phase 3 REVEAL study, with data expected in the second half of 2027
85 programs · 108 verified studies
| Company | Drug | Indication | Phase | Study status | Timing | Registry |
|---|---|---|---|---|---|---|
| IONS IONIS PHARMACEUTICALS INC | Alicaforsen | Crohn's Disease | Phase3 | Completed | Actual study completion2002-04-27 | NCT00048113 |
| IONS IONIS PHARMACEUTICALS INC | Alicaforsen | Crohn's Disease | Phase3 | Completed | Study completionNot provided | NCT00048295 |
| IONS IONIS PHARMACEUTICALS INC | Alicaforsen | Ulcerative Colitis | Phase2 | Completed | Actual study completion2005-03-24 | NCT00063414 |
| IONS IONIS PHARMACEUTICALS INC | Alicaforsen | Ulcerative Colitis | Phase2 | Completed | Actual study completion2004-10-11 | NCT00063830 |
| IONS IONIS PHARMACEUTICALS INC | APOC-III-L-Rx | Elevated Triglycerides (TG) | Phase1 | Completed | Actual study completion2018-04-30 | NCT02900027 |
| IONS IONIS PHARMACEUTICALS INC | BIIB094 | Parkinson's Disease | Phase1 | Completed | Actual study completion2024-08-12 | NCT03976349 |
| IONS IONIS PHARMACEUTICALS INC | Carboplatin | Lung Cancer | Phase3 | Completed | Actual study completion2002-09-09 | NCT00017407 |
| IONS IONIS PHARMACEUTICALS INC | Carboplatin | Non-small Cell Lung Cancer | Phase1 / Phase2 | Completed | Actual study completion2013-01 | NCT01234038 |
| IONS IONIS PHARMACEUTICALS INC | daily OAD (metformin and/or sulfonylurea) | Type 2 Diabetes Mellitus; Obese | Phase2 | Completed | Actual study completion2015-02 | NCT01918865 |
| IONS IONIS PHARMACEUTICALS INC | Docetaxel | Castrate-Resistant Prostate Cancer | Phase1 / Phase2 | Completed | Actual study completion2013-12 | NCT01234025 |
Phase
Phase3Study status
CompletedIONIS PHARMACEUTICALS INC
IndicationCrohn's Disease
Actual study completion2002-04-27
Phase
Phase3Study status
CompletedIONIS PHARMACEUTICALS INC
IndicationCrohn's Disease
Study completionNot provided
Phase
Phase2Study status
CompletedIONIS PHARMACEUTICALS INC
IndicationUlcerative Colitis
Actual study completion2005-03-24
Phase
Phase2Study status
CompletedIONIS PHARMACEUTICALS INC
IndicationUlcerative Colitis
Actual study completion2004-10-11
Phase
Phase1Study status
CompletedIONIS PHARMACEUTICALS INC
IndicationElevated Triglycerides (TG)
Actual study completion2018-04-30
Phase
Phase1Study status
CompletedIONIS PHARMACEUTICALS INC
IndicationParkinson's Disease
Actual study completion2024-08-12
Phase
Phase3Study status
CompletedIONIS PHARMACEUTICALS INC
IndicationLung Cancer
Actual study completion2002-09-09
Phase
Phase1 / Phase2Study status
CompletedIONIS PHARMACEUTICALS INC
IndicationNon-small Cell Lung Cancer
Actual study completion2013-01
Phase
Phase2Study status
CompletedIONIS PHARMACEUTICALS INC
IndicationType 2 Diabetes Mellitus; Obese
Actual study completion2015-02
Phase
Phase1 / Phase2Study status
CompletedIONIS PHARMACEUTICALS INC
IndicationCastrate-Resistant Prostate Cancer
Actual study completion2013-12
40 unverified sponsor matches remain unlinked.